메뉴 건너뛰기




Volumn 11, Issue 3, 2013, Pages 286-290

Counterpoint: Prostate-specific antigen velocity is not of value for early detection of cancer

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

EID: 84875896012     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0040     Document Type: Review
Times cited : (2)

References (23)
  • 1
    • 70349295163 scopus 로고    scopus 로고
    • Prostate-specific antigen velocity for early detection of prostate cancer: Result from a large, representative, population-based cohort
    • Vickers AJ, Wolters T, Savage CJ, et al. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol 2009;56:753-760.
    • (2009) Eur Urol , vol.56 , pp. 753-760
    • Vickers, A.J.1    Wolters, T.2    Savage, C.J.3
  • 2
    • 39749180009 scopus 로고    scopus 로고
    • Long-term prediction of prostate cancer: Prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population
    • Ulmert D, Serio AM, O'Brien MF, et al. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol 2008;26:835-841.
    • (2008) J Clin Oncol , vol.26 , pp. 835-841
    • Ulmert, D.1    Serio, A.M.2    O'Brien, M.F.3
  • 3
    • 58549106592 scopus 로고    scopus 로고
    • A systematic review of pretreatment PSA velocity and doubling time as predictors for prostate cancer
    • Vickers AJ, Savage C, O'Brien MF, et al. A systematic review of pretreatment PSA velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009;27:398-403.
    • (2009) J Clin Oncol , vol.27 , pp. 398-403
    • Vickers, A.J.1    Savage, C.2    O'Brien, M.F.3
  • 4
    • 33646459214 scopus 로고    scopus 로고
    • Assessing prostate cancer risk: Results from the Prostate Cancer PreventionTrial
    • Thompson IM, Ankerst D, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer PreventionTrial. J Natl Cancer Inst 2006;98:529-534.
    • (2006) J Natl Cancer Inst , vol.98 , pp. 529-534
    • Thompson, I.M.1    Ankerst, D.2    Chi, C.3
  • 5
    • 33846862475 scopus 로고    scopus 로고
    • Prostate specific antigen velocity threshold for predicting prostate cancer in young men
    • Loeb S, Roehl KA, Catalona WJ, et al. Prostate specific antigen velocity threshold for predicting prostate cancer in young men. J Urol 2007;177:899-902.
    • (2007) J Urol , vol.177 , pp. 899-902
    • Loeb, S.1    Roehl, K.A.2    Catalona, W.J.3
  • 6
    • 79953205605 scopus 로고    scopus 로고
    • Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively
    • O'Brien MF, Cronin AM, Fearn PA, et al. Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively. Int J Cancer 2011;128:2373-2381.
    • (2011) Int J Cancer , vol.128 , pp. 2373-2381
    • O'Brien, M.F.1    Cronin, A.M.2    Fearn, P.A.3
  • 7
    • 68949121119 scopus 로고    scopus 로고
    • Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy
    • O'Brien MF, Cronin AM, Fearn PA, et al. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol 2009;27:3591-3597.
    • (2009) J Clin Oncol , vol.27 , pp. 3591-3597
    • O'Brien, M.F.1    Cronin, A.M.2    Fearn, P.A.3
  • 8
    • 77956396162 scopus 로고    scopus 로고
    • Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program
    • Ross AE, Loeb S, Landis P, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010;28:2810-2816.
    • (2010) J Clin Oncol , vol.28 , pp. 2810-2816
    • Ross, A.E.1    Loeb, S.2    Landis, P.3
  • 9
    • 34247630061 scopus 로고    scopus 로고
    • Prostate-specific antigen levels as a predictor of lethal prostate cancer
    • Fall K, Garmo H, Andren O, et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 2007;99:526-532.
    • (2007) J Natl Cancer Inst , vol.99 , pp. 526-532
    • Fall, K.1    Garmo, H.2    Andren, O.3
  • 10
    • 70349313376 scopus 로고    scopus 로고
    • Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era
    • Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009;27:4300-4305.
    • (2009) J Clin Oncol , vol.27 , pp. 4300-4305
    • Stephenson, A.J.1    Kattan, M.W.2    Eastham, J.A.3
  • 11
    • 77956630147 scopus 로고    scopus 로고
    • Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy
    • Vickers AJ, Wolters T, Savage CJ, et al. Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy. J Urol 2010;184:907-912.
    • (2010) J Urol , vol.184 , pp. 907-912
    • Vickers, A.J.1    Wolters, T.2    Savage, C.J.3
  • 12
    • 79952833310 scopus 로고    scopus 로고
    • An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection
    • Vickers AJ, Till C, Tangen CM, et al. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst 2011;103:462-469.
    • (2011) J Natl Cancer Inst , vol.103 , pp. 462-469
    • Vickers, A.J.1    Till, C.2    Tangen, C.M.3
  • 13
    • 57649149841 scopus 로고    scopus 로고
    • Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam)
    • Wolters T, Roobol MJ, Bangma CH, et al. Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam). Eur Urol 2009;55:385-392.
    • (2009) Eur Urol , vol.55 , pp. 385-392
    • Wolters, T.1    Roobol, M.J.2    Bangma, C.H.3
  • 14
    • 84860626358 scopus 로고    scopus 로고
    • A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy
    • Auprich M, Augustin H, Budaus L, et al. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. BJU Int 2012;109:1627-1635.
    • (2012) BJU Int , vol.109 , pp. 1627-1635
    • Auprich, M.1    Augustin, H.2    Budaus, L.3
  • 15
    • 44649157173 scopus 로고    scopus 로고
    • Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program
    • Eggener SE, Yossepowitch O, Roehl KA, et al. Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program. Urology 2008;71:1016-1019.
    • (2008) Urology , vol.71 , pp. 1016-1019
    • Eggener, S.E.1    Yossepowitch, O.2    Roehl, K.A.3
  • 16
    • 78649997059 scopus 로고    scopus 로고
    • The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: Results from the REDUCE study
    • Andriole GL, Bostwick D, Brawley OW, et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol 2011;185:126-131.
    • (2011) J Urol , vol.185 , pp. 126-131
    • Andriole, G.L.1    Bostwick, D.2    Brawley, O.W.3
  • 17
    • 77649099098 scopus 로고    scopus 로고
    • NCCN clinical practice guidelines in oncology: Prostate cancer early detection
    • To view the most recent version of these guidelines, visit NCCN.org
    • Kawachi MH, Bahnson RR, Barry M, et al. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection. J Natl Compr Canc Netw 2010;8:240-262. To view the most recent version of these guidelines, visit NCCN.org.
    • (2010) J Natl Compr Canc Netw , vol.8 , pp. 240-262
    • Kawachi, M.H.1    Bahnson, R.R.2    Barry, M.3
  • 18
    • 33750582502 scopus 로고    scopus 로고
    • Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability
    • Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006;98:1521-1527.
    • (2006) J Natl Cancer Inst , vol.98 , pp. 1521-1527
    • Carter, H.B.1    Ferrucci, L.2    Kettermann, A.3
  • 19
    • 80655149501 scopus 로고    scopus 로고
    • Re: An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection
    • author reply 1637
    • Loeb S, Metter EJ, Carter HB. Re: an empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst 2011;103:1636-1637; author reply 1637.
    • (2011) J Natl Cancer Inst , vol.103 , pp. 1636-1637
    • Loeb, S.1    Metter, E.J.2    Carter, H.B.3
  • 20
    • 84857034566 scopus 로고    scopus 로고
    • Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer
    • discussion 513-514
    • Loeb S, Metter EJ, Kan D, et al. Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer. BJU Int 2012;109:508-513; discussion 513-514.
    • (2012) BJU Int , vol.109 , pp. 508-513
    • Loeb, S.1    Metter, E.J.2    Kan, D.3
  • 21
    • 22844433445 scopus 로고    scopus 로고
    • Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy
    • D'Amico AV, Renshaw AA, Sussman B, et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005;294:440-447.
    • (2005) JAMA , vol.294 , pp. 440-447
    • D'Amico, A.V.1    Renshaw, A.A.2    Sussman, B.3
  • 22
    • 3042727071 scopus 로고    scopus 로고
    • Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy
    • D'Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351:125-135.
    • (2004) N Engl J Med , vol.351 , pp. 125-135
    • D'Amico, A.V.1    Chen, M.H.2    Roehl, K.A.3
  • 23
    • 33845466234 scopus 로고    scopus 로고
    • PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section
    • Khatami A, Aus G, Damber JE, et al. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 2007;120:170-174.
    • (2007) Int J Cancer , vol.120 , pp. 170-174
    • Khatami, A.1    Aus, G.2    Damber, J.E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.